Hemab Therapeutics Holdings, Inc. Common Stock Cash Flow Statement

Operating, investing, and financing cash movements

Metric	Q1 '25	Q1 '26
Other non-cash income (expense)	-$381.0K	—
Other non-cash income (expense)	-$381.0K	—
Change in accounts payable	$2.9M	-$52.0K
Change in operating lease liabilities	-$139.0K	-$157.0K
Change in other assets	$800.0K	$1.0M
Change in other liabilities	-$17.0K	—
Other working capital changes	-$381.0K	—
Depreciation and amortization	$75.0K	$73.0K
Other Non-Cash Income (Expense)	-$381.0K	—
Other Non-cash Income (Expense)	-$381.0K	—
Other Non-cash Income (Expense)	-$381.0K	—
Change in other non-current liabilities	-$17.0K	—
Net cash from operating activities	-$13.0M	-$21.6M
Net income	-$15.3M	-$22.7M
Other non-cash income (expense)	-$381.0K	—
Accretion Of Discount On Available For Sale Debt Securities	$208.0K	$816.0K
Employee retirement benefits	$459.0K	$1.3M
Operating lease liabilities	-$139.0K	-$157.0K
Current liabilities	-$434.0K	$434.0K
Other long-term liabilities	-$17.0K	—
Prepaid expenses and other current assets	$65.0K	-$1.2M
Other Noncash Income (Expense)	-$381.0K	—
Sales-type Lease, Selling Profit (Loss)	-$140.0K	-$153.0K
Other Non-cash Income and Expense	-$381.0K	—
Pension and postretirement benefit expense	$459.0K	$1.3M
Other Non-Cash Adjustments	-$381.0K	—
Other Non-Cash Income and Expense	-$381.0K	—

Metric	Q1 '25	Q1 '26
Capital expenditures	$16.0K	$112.0K
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$14.0M	—
Net cash from investing activities	-$6.0M	-$15.8M
Proceeds from maturities/sales of investments	$14.0M	—
Purchases of investments	$19.9M	$15.7M

Metric	Q1 '25	Q1 '26
Finance Lease, Principal Payments	$29.0K	$46.0K
Payment Of Offering Costs	—	$414.0K
Finance lease prepayments	$29.0K	$46.0K
Net cash from financing activities	-$29.0K	-$460.0K
Payments for finance leases	$29.0K	$46.0K

Metric	Q1 '25	Q1 '26
Free cash flow	-$13.0M	-$21.7M

Metric	Q1 '25	Q1 '26
Effect of exchange rate changes on cash	—	-$223.0K
Net increase (decrease) in cash	-$19.1M	-$38.1M
Deferred Offering Costs Included In Accrued Expenses And Accounts Payable	—	$2.3M

Metric	Q1 '25	Q1 '26
Interest paid	$3.0K	—